These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 23512740)

  • 1. Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.
    Lv Q; Zhang B
    Neurosci Bull; 2013 Oct; 29(5):661-9. PubMed ID: 23512740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myths and realities of continuous dopaminergic stimulation.
    Pirtošek Z
    Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S68-71. PubMed ID: 20083012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing Parkinson's disease with continuous dopaminergic stimulation.
    Wolters E; Lees AJ; Volkmann J; van Laar T; Hovestadt A
    CNS Spectr; 2008 Apr; 13(4 Suppl 7):1-14; quiz 15-6. PubMed ID: 18408654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous dopamine-receptor stimulation in advanced Parkinson's disease.
    Nutt JG; Obeso JA; Stocchi F
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S109-15. PubMed ID: 11052228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Continuous dopaminergic stimulation - clinical experience].
    Bogucki A; Sławek J
    Neurol Neurochir Pol; 2010; 44(4):385-95. PubMed ID: 20827612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities.
    Olanow CW; Calabresi P; Obeso JA
    Mov Disord; 2020 Oct; 35(10):1731-1744. PubMed ID: 32816321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
    Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
    Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.
    Olanow CW; Obeso JA; Stocchi F
    Lancet Neurol; 2006 Aug; 5(8):677-87. PubMed ID: 16857573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease.
    van Wamelen DJ; Grigoriou S; Chaudhuri KR; Odin P
    J Parkinsons Dis; 2018; 8(s1):S65-S72. PubMed ID: 30584160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease.
    Obeso JA; Grandas F; Herrero MT; Horowski R
    Eur J Neurosci; 1994 Jun; 6(6):889-97. PubMed ID: 7952277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease.
    Calandrella D; Antonini A
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S120-2. PubMed ID: 22166407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.
    Gershanik O; Jenner P
    Eur J Neurol; 2012 Dec; 19(12):1502-8. PubMed ID: 22221452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous dopaminergic stimulation and novel formulations of dopamine agonists.
    Stocchi F
    J Neurol; 2011 May; 258(Suppl 2):S316-22. PubMed ID: 21560062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias.
    Barroso SDS; Lopes LES; Santos KS; Gomes MZ
    Expert Opin Ther Pat; 2019 Dec; 29(12):979-985. PubMed ID: 31694421
    [No Abstract]   [Full Text] [Related]  

  • 20. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
    Stathis P; Konitsiotis S; Antonini A
    Expert Rev Neurother; 2015 Feb; 15(2):207-13. PubMed ID: 25578445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.